Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Chinese pediatric moderate-to-severe plaque psoriasis (real-world, Phase IV)
CTR20221825Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Jul 2022; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20221825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221825.